Biote operates a hybrid business model combining clinic-based hormone optimization procedures and an expanding dietary supplement business. The integration of a proprietary manufacturing facility provides a defensible margin advantage, though the core medical procedures and supplements face moderat…
Biote Corp. (BTMD) Q2 2025: Procedure Revenue Declines 8.4% Amid Strategic Reorganization
Biote's Q2 2025 results reflect a transitional phase with procedure revenue pressure offset by robust dietary supplement growth and improved margins. The company’s organizational restructuring aims to realign the commercial team for sustainable growth despite near-term disruptions. Adjusted guidance signals cautious optimism as the firm balances operational challenges with strategic investments.
Summary
- Commercial Realignment Underway: Comprehensive reorganization targets growth acceleration and operational discipline.
- Margin Expansion Through Vertical Integration: Manufacturing integration drives gross profit improvement despite revenue headwinds.
- Growth Transition Evident: Dietary supplement expansion partly offsets procedure revenue softness as strategic initiatives take hold.
Business Overview
Biote Corp. operates in the preventive healthcare sector, specializing in personalized hormone optimization and therapeutic wellness solutions. The company generates revenue primarily through two segments: procedure services delivered via clinics and dietary supplement sales, with the latter increasingly driven by e-commerce channels. Biote’s business model leverages certified medical providers to deliver its offerings, aiming to address the growing market for healthy aging and wellness.
Performance Analysis
In Q2 2025, Biote reported total revenue of $48.9 million, nearly flat year-over-year but marked by divergent trends within its core segments. Procedure revenue declined 8.4%, reflecting challenges in clinic attrition, slower new clinic additions, and reduced procedure volumes. Conversely, dietary supplement revenue surged 30.4% to approximately $10.7 million, fueled by e-commerce growth and representing a meaningful offset to procedural softness.
The company achieved a significant gross profit margin expansion to 71.6%, up 280 basis points from the prior year, primarily driven by vertical integration of its 503B manufacturing facility. This operational leverage supported a 19.1% increase in Adjusted EBITDA to $15.2 million and a margin improvement to 31.1%. General and administrative expenses declined 12.2%, aided by the timing shift of the annual marketing event and headcount reductions related to the restructuring.
- Procedure Revenue Headwinds: Clinic attrition and volume declines were exacerbated by organizational changes and prior software disruptions.
- Dietary Supplement Momentum: The segment’s mid-teens growth rate outlook underscores its strategic importance as a growth engine.
- Profitability Gains: Margin expansion highlights the benefits of manufacturing integration and disciplined cost management.
Overall, the results illustrate a company in transition, balancing near-term disruptions with foundational improvements intended to drive future growth.
Executive Commentary
"While progress will not be linear and will take time, I have been pleased to see renewed energy and enthusiasm across our organization, and our team is unified and committed in pursuit of our strategic objectives."
Brett Christensen, Chief Executive Officer
"Adjusted EBITDA and adjusted EBITDA margin increased from the prior-year quarter due to the shift of our 2025 annual marketing event, higher gross profit margin, and reduced operating expenses."
Bob Peterson, Chief Financial Officer
Strategic Positioning
1. Organizational Restructuring to Drive Growth
Biote initiated a comprehensive reorganization in May 2025 aimed at strengthening commercial execution and fostering a high-performance culture. Key changes include new leadership appointments, revamped sales compensation aligned with growth objectives, and enhanced sales training. These initiatives are designed to accelerate new clinic additions and increase procedure volumes, addressing the current attrition and volume headwinds.
2. Vertical Integration of Manufacturing
The company’s 503B manufacturing facility integration continues to deliver cost efficiencies and margin expansion. Current pellet penetration in verticalized manufacturing remains in the low 40% to 50% range, with plans to increase this share starting in Q3. This verticalization supports improved gross margins and provides a competitive cost advantage.
3. Expanding Dietary Supplement Business
Dietary supplement sales grew over 30% year-over-year, driven largely by e-commerce channels. Management expects mid-teens growth for this segment in 2025, reflecting its strategic role as a complementary and faster-growing revenue stream alongside procedures.
4. Commercial Team Realignment and Focus
The sales force restructuring includes smaller territories, growth-focused compensation plans, and consolidated leadership to ensure consistent messaging and accountability. These changes aim to improve sales productivity, reduce attrition, and better support existing and new clinics.
5. Long-Term Value Proposition Enhancements
Beyond immediate operational changes, Biote is investing in initiatives to improve retention and clinic engagement through stronger value propositions. These longer-term efforts seek to create a more sticky customer base and facilitate sustainable growth.
Key Considerations
Biote’s Q2 results underscore a pivotal transition year marked by strategic realignment and operational challenges.
Key Considerations:
- Transition Year Impact: Reorganization and software implementation disruptions have temporarily suppressed procedure revenue growth.
- Margin Leverage: Vertical integration and cost discipline are driving profitability despite revenue pressures.
- Sales Force Evolution: Structural changes to the commercial team aim to shift focus from maintenance to aggressive growth.
- Dietary Supplement Growth: This segment’s acceleration diversifies revenue and reduces dependence on procedures.
- Uncertain Timing: Management refrains from projecting near-term volume recovery, emphasizing the need to observe early KPIs.
Risks
Risks include continued procedure revenue declines if clinic attrition and volume do not stabilize, potential delays in realizing benefits from the restructuring, and competitive pressures in hormone optimization and wellness markets. The company’s transition involves inherent execution risks that could affect revenue and margin trajectories.
Forward Outlook
For Q3 2025, Biote anticipates procedure revenue trends to remain similar to Q2, with dietary supplement growth continuing at a strong but moderating pace. For full-year 2025, the company updated guidance to revenue above $190 million and Adjusted EBITDA above $50 million, reflecting expected high single-digit declines in procedure revenue and mid-teens growth in dietary supplements.
- Procedure revenue expected to decline at a high single-digit rate for 2025.
- Dietary supplements projected to grow at a mid-teens percentage rate in 2025.
Management highlighted ongoing efforts to align the commercial organization and emphasized that 2025 remains a transition year as strategic initiatives begin to take effect.
Takeaways
Biote’s Q2 2025 results reveal a company navigating a challenging but necessary transformation to drive sustainable growth.
- Operational Disruptions Suppress Procedure Revenue: The combined impact of clinical software rollout and organizational restructuring has tempered procedure volume and clinic additions, a critical revenue driver.
- Strategic Investment in Commercial and Manufacturing Capabilities: Vertical integration and sales force realignment are foundational moves that improve margins and position Biote for future growth.
- Monitoring Early Indicators Will Be Crucial: Investors should watch for improvements in new clinic starts, retention rates, and procedure volumes as leading signals of the company’s turnaround progress.
Conclusion
Biote’s Q2 performance reflects a deliberate, though disruptive, transition focused on strengthening the commercial engine and operational foundation. While procedure revenue faces near-term headwinds, margin gains and dietary supplement growth provide partial offsets. The company’s strategic initiatives set the stage for a potential recovery and sustainable long-term growth.
Industry Read-Through
Biote’s experience highlights broader sector challenges in hormone optimization and therapeutic wellness, where software implementations and organizational changes can temporarily unsettle growth trajectories. The positive margin impact from vertical manufacturing integration may serve as a model for peers seeking cost efficiencies. Additionally, the expansion of dietary supplements through e-commerce channels signals a growing sub-segment that other industry players may increasingly prioritize to diversify revenue streams and mitigate procedural volume volatility.